Please assess the completion status of the following clinical trial:

Trial Title: Bevacizumab (Avastin) and RAD001(Everolimus)in the Treatment of Advanced Clear Cell Renal Carcinoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically documented metastatic or unresectable locally recurrent clear cell renal carcinoma.~* In patients with mixed histologies, the clear cell component must comprise ≥ 75% of the cancer~* Previous nephrectomy is required with the following exceptions:~* Primary tumor \< 5cm~* Extensive liver ( \> 30% of liver parenchyma)or~* Multiple (\> 5) bone metastases, making nephrectomy a clinically contraindicated procedure~* Patients may have had a maximum of 1 previous systemic regimen for metastatic disease~* Patients may not have received previous bevacizumab. However, patients who have received other agents with anti-angiogenic activity (eg. sorafenib, SU11248, AG-013736, PTK787, thalidomide) as part of first-line treatment are eligible~* Patients may not have received previous treatment with m-TOR inhibitors.~* ECOG performance status 0 or 1~* Measurable disease~* Adequate liver, kidney and bone marrow function~* No previous systemic treatment or radiation therapy for at least 2 weeks prior to study entry~* Patients must be able to understand the nature of this study and give written informed consent~Exclusion Criteria:~* Age \< 18 years~* Treatment with \> 1 previous systemic regimen for metastatic renal carcinoma~* History of acute myocardial infarction within 6 months~* Clinically significant cardiovascular disease~* History of stroke within 6 months~* Patients with active brain metastases~* Patients with meningeal metastases~* Women who are pregnant or lactating~* Patients who have been treated within 5 years for other invasive cancers~* Patients with history or evidence by physical examination of CNS disease~* Patients with clinical history of hemoptysis or hematemesis~* Patients with history of deep vein thrombosis or thromboembolic disease requiring full dose anticoagulation~* Patients with major surgical procedures, open biopsies, or significant traumatic injuries within 28 days or anticipated need for major surgical procedure during the course of the study~* Patients with peg-tubes or G-tubes~* Patients are ineligible if a fine needle aspiration biopsy has been performed within seven days~* Patients with proteinuria~* Patients with any non-healing wound, ulcer, or long-bone fracture~* Patients with any history of a bleeding diathesis or coagulopathy~* History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months~* Patients who have received any other experimental drug within 28 days of starting treatment~* History of any other severe and/or uncontrolled medical disease~* History of HIV infection~* Chronic treatment with steroids or other immunosuppressive agents~* Patients with impaired GI function that compromises the ability to swallow or absorb RAD001~* Patients who are unwilling or unable to comply with the protocol

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Bevacizumab and RAD001 (Type: EXPERIMENTAL): Bevacizumab 10mg/kg, IV infusion, every 2 weeks RAD001 10 mg by mouth daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete